In line with an antitumoural action of DUSP7, a recent work demonstrated that in CRC with SMAD4 deletion, SETD2, a histone methyltransferase, promotes the transcription of DUSP7, leading to inactivation of the RAS/ERK pathway and reduced tumour growth [63]. This evidence concerns the gene SETD2 and neoplasm.